

48,500,000 Results Any time ▾

[Thymosin alpha 1 \(Tα1\) reduces the mortality of severe ...](#)

<https://www.immunology.ox.ac.uk/covid-19/covid-19...>

Severe and critical COVID-19 patients treated with Thymosin α 1 (10mg daily for >7 days) had a lower mortality rate and less need of mechanical ventilation than patients without Thymosin α 1. 2. Tα1 treatment was associated with an increase in T lymphocyte counts, ...

[New Research Paper Suggests RegeneRx's Thymosin Beta 4 ...](#)

<https://markets.businessinsider.com/news/stocks/...>

Sep 08, 2020 · While men and women have the same prevalence, men with COVID-19 are more at risk for worse outcomes and death, independent of age. "That men with COVID-19 are 2.4 times more likely ...

Search Tools

Turn off Hover Translation (关闭取词)

ALL IMAGES VIDEOS

45,900,000 Results Any time

Thymosin alpha 1 (Tα1) reduces the mortality of severe ...
<https://www.immunology.ox.ac.uk/covid-19/covid-19...>
 Severe and critical COVID-19 patients treated with Thymosin α 1 (10mg daily for >7 days) had a lower mortality rate and less need of mechanical ventilation than patients without Thymosin α 1. Tα1 treatment was associated with an increase in T lymphocyte counts, evident in ...

New Research Paper Suggests RegeneRx's Thymosin Beta 4 May ...
<https://markets.businessinsider.com/news/stocks/...>
 Sep 08, 2020 - The research, entitled A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm, was published in eLife 2020;9:e59177 DOI: 10.7554/eLife.59177.

New Research Paper Suggests RegeneRx's Thymosin Beta 4 May ...
<https://www.pharmalive.com/new-research-paper...>
 Sep 08, 2020 - New Research Paper Suggests RegeneRx's Thymosin Beta 4 May be Useful in Treating COVID-19. ROCKVILLE, Md., Sept. 8, 2020 /PRNewswire/ - RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced today that a multi-institutional team of scientists from eight American ...

Compounding Activities | COVID-19 | FDA
<https://www.fda.gov/drugs/coronavirus-covid-19...>
 FDA has concerns about the use of certain drugs prepared by compounders to treat patients with COVID-19: Thymosin-alpha 1 is not a component of an approved drug, and thymosin does not meet the ...

Therapeutic Options for COVID-19 Patients | CDC
<https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html>
 Dec 04, 2020 - FDA has approved one drug, remdesivir (Veklury), for the treatment of COVID-19 in certain situations. Early effective treatment of any disease can help avert progression to more serious illness, especially for patients at high risk of disease progression and severe illness, with the additional benefit of reducing the burden on healthcare systems.

Clinical remission of a critically ill COVID-19 patient ...
<https://pubmed.ncbi.nlm.nih.gov/32756149>
 Rationale: The COVID-19 cases increased very fast in January and February 2020. The mortality among critically ill patients, especially the elder ones, is relatively high. Considering many patients died of severe inflammation response, it is urgent to develop effective therapeutic strategies for these patients.

COVID-19 therapeutics tracker | RAPS
<https://www.raps.org/.../covid-19-therapeutics-tracker>
 The South Korea Ministry of Food and Drug Safety has authorized Regkirona (regdanimab), a human monoclonal antibody. Several large international trials are underway. The largest, SOLIDARITY, is led by the World Health Organization (WHO). More than 100 countries have joined SOLIDARITY to evaluate high-profile treatment candidates for COVID-19.

Treatments for COVID-19 - Harvard Health
<https://www.health.harvard.edu/diseases-and-conditions/treatments-for-covid-19>
 Mar 04, 2021 - Remdesivir in October 2020, the FDA approved the antiviral drug remdesivir to treat COVID-19. The drug may be used to treat adults and children ages 12 and older and weighing at least 88 pounds, who have been hospitalized for COVID-19. Clinical trials suggest that in these patients, remdesivir may modestly speed up recovery time.

COVID-19 (coronavirus) drugs: Are there any that work ...
<https://www.mayoclinic.org/diseases-conditions/...>
 Drugs to prevent COVID-19. Researchers are studying drugs to prevent COVID-19 before and after exposure to the virus. It's not known if any of these will prove to be effective against COVID-19. It's critical to complete medical studies to determine whether any of ...

COVID-19 Registered Trials - and analysis - The Centre for ...
<https://www.cebm.net/covid-19/registered-trials-and-analysis>
 61 rows - The disease it causes has been called COVID-19. The latest figures (17 March 2020) suggest ...

TYPE OF MEDICINE	MECHANISM OF ACTION	NO. OF TRIALS
Immunoglobulin	Contains nonspecific antibodies; proposed to block viral Fc rece...	1
Interferons	Activate cytoplasmic enzymes affecting viral messenger RNA tra...	4
Interleukin-2	Multiple anti-inflammatory actions	1
Favipiravir	Inhibitor of viral RNA-dependent RNA polymerase; typically used L...	4

See all 61 rows on www.cebm.net

Coronavirus Disease 2019 (COVID-19) | FDA
<https://www.fda.gov/.../coronavirus-disease-2019-covid-19>
 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 ...

NETs a Possible Therapeutic Target for COVID-19 Thrombosis?
<https://www.medscape.com/viewarticle/943407>

Search Tools

Turn off Hover Translation (关闭)

Add the Olive with Bing extension >

Make a difference for a nonprofit, simply by searching on Bing

MAYBE LATER YES

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 62978

Manuscript Type: CASE REPORT

Thymosin as a possible therapeutic drug for COVID-19: A case report

Zheng QN *et al.* Thymosin as a drug for COVID-19

Qiong Na Zheng, Mei Yan Xu, Fang Min Gan, Sha Sha Ye, Hui Zhao

Abstract

BACKGROUND

There are no effective antiviral therapies for the coronavirus disease-2019 (COVID-19) at present. Although most patients with COVID-19 have a mild or moderate course of disease, up to 5%–10% of patients may have a serious and potentially life-threatening condition, indicating an urgent need for effective therapeutic drugs. The therapeutic effect of thymosin on COVID-19 has not been previously studied. In this study, for the

Match Overview

1	Internet 56 words crawled on 10-Nov-2020 www.wjnet.com	4%
2	Internet 23 words crawled on 20-Jun-2019 ipublishing.tbob.com/windows.net	2%
3	Internet 21 words crawled on 14-Feb-2021 academic.oup.com	1%
4	Internet 20 words crawled on 06-Jan-2021 www.jci.org	1%
5	Crossref 16 words "Diagnostic Imaging of Novel Coronavirus Pneumonia", Springer Science and Business Media LLC, 2020	1%
6	Crossref 16 words "Thymic Hormones and Lymphokines", Springer Science and Business Media LLC, 1984	1%
7	Crossref Posted Content 14 words Ke Zhao, Ke Rao, Xin Chen, Si Chen, Haifang Xu, Pir... ry Hepatic Cholangiocarcinoma in a Male Patient: A Case Re	1%
8	Internet 12 words crawled on 22-Dec-2019 lessera.spandidos-publications.com	1%

国内版 国际版

Thymosin as a possible therapeutic drug for COVID-19: A case report



ALL IMAGES VIDEOS

44,400,000 Results Any time ▾

Thymosin alpha 1 (Tα1) reduces the mortality of severe ...

<https://www.immunology.ox.ac.uk/covid-19/covid-19...> ▾

Severe and critical COVID-19 patients treated with Thymosin α 1 (10mg daily for >7 days) had a lower mortality rate and less need of mechanical ventilation than patients without Thymosin α 1. 2. Tα1 treatment was associated with an increase in T lymphocyte counts, evident in ...

New Research Paper Suggests RegeneRx's Thymosin Beta 4 ...

<https://markets.businessinsider.com/news/stocks/...> ▾

Sep 08, 2020 · The research, entitled A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm, was published in eLife 2020;9:e59177 DOI: 10.7554/eLife.59177.

New Research Paper Suggests RegeneRx's Thymosin Beta 4 ...

<https://www.pharmalive.com/new-research-paper...> ▾

Sep 08, 2020 · While men and women have the same prevalence, men with COVID-19 are more at risk for worse outcomes and death, independent of age. "That men with COVID-19 are 2.4 times more likely than women to die from the virus is extremely interesting because the gene for Thymosin beta 4 resides on the X chromosome.

Clinical remission of a critically ill COVID-19 patient ...

<https://pubmed.ncbi.nlm.nih.gov/32756149>

Rationale: The COVID-19 cases increased very fast in January and February 2020. The mortality among critically ill patients, especially the elder ones, is relatively high. Considering many patients died of severe inflammation response, it is urgent to develop effective therapeutic strategies for these patients.

Cited by: 106 Author: Bing Liang, Junhui Chen, Tao Li, Haiying ...

Publish Year: 2020

Therapeutic Options for COVID-19 Patients | CDC

<https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html> ▾

Feb 11, 2020 · FDA has approved one drug, remdesivir (Veklury), for the treatment of COVID-19 in certain situations. Early effective treatment of any disease can help avert progression to more serious illness, especially for patients at high risk of disease progression and severe illness, with the additional benefit of reducing the burden on healthcare systems.